• NMPA accepts NDA for biosimilar product candidate of Rituximab biospectrumasia
    June 28, 2019
    IBI301 is a recombinant human-mouse chimeric anti-cell surface protein (anti-CD20) monoclonal antibody for injection co-developed by Lilly and Innovent for the treatment of non-Hodgkin's lymphoma (NHL) and other diseases.
PharmaSources Customer Service